Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Report
October 22, 2014
Anti-VEGF Agents: How Does Cost Versus Dosing Impact the Wet AMD Treatment Algorithm Among Retinal Specialists in the United States? | Physician & Payer Forum | US | 2014
While Genentech’s Lucentis continues to be the gold-standard treatment for wet age-related macular degeneration (AMD) in the United States, off-label use of Genentech’s Avastin (often…
Report
June 24, 2014
Wet Age-Related Macular Degeneration | Treatment Algorithms | Claims Data Analysis | US | 2014
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. More than half of advanced AMD patients suffer the wet (exudative, neovascular) form of the disease,…
